Nektar Therapeutics – pharmaceutical daily

April 15, 2022 Off

Nektar and BMS End Clinical Development of Bempegaldesleukin in Combination with Opdivo

By Author

Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) have announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.

March 14, 2022 Off

BMS’s and Nektar Therapeutics’s Join Study of Bempegaldesleukin in Combination with Opdivo for Treatment of Melanoma Failed to Meet Expectations

By Dino Mustafić

Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have announced an update following the first analysis of the…

March 13, 2017 Off

Biotechnology companies stocks report

By Dino Mustafić

iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.